ArticleFrontiers in medicine2026
Malignancy in anti-synthetase syndrome: clinical features and prognostic impact from a multicenter retrospective study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To delineate the clinical characteristics, identify risk factors (including the exploratory role of anti-Ro-52 antibody), and assess the prognostic implications of malignancy in patients with anti-synthetase syndrome (ASyS). Methods: In this retrospective multicenter study, patients with idiopathic inflammatory myopathies (IIM) were analyzed, comprising 103 ASyS and 261 non-ASyS patients [including dermatomyositis ( Results: Malignancy prevalence was 15.5% (16/103) in ASyS patients vs. 9.2% (24/261) in non-ASyS patients ( Conclusion: Anti-synthetase syndrome is an independent risk factor for malignancy in patients with myositis, challenging the traditional view of ASyS as a low-risk subtype. Systematic malignancy screening is warranted for all ASyS patients, particularly those over 60 years of age. The role of anti-Ro-52 as an independent predictor was not confirmed and requires further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.